Magic mushroom microdoses could soothe End-of-Life anxiety

NCT ID NCT07063862

Recruiting now Symptom relief Sponsor: Bruyère Health Research Institute. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether daily low-dose psilocybin (2-3 mg) can reduce psychological distress in 120 adults with advanced illness who have 2-12 months to live. Participants take the drug four days a week for two weeks, without therapy. The study compares psilocybin to a placebo to see if it safely improves mood and well-being.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin (a psychedelic compound from 'magic mushrooms')
What this could lead to: If it works, this could offer a quick, safe, and accessible way to ease anxiety, depression, and loss of purpose in people with advanced illness.
What could go wrong: This is a small, early-phase trial with only 120 participants. The low dose may not work as well as high-dose psilocybin, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSYCHOLOGICAL DISTRESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSYCHOLOGICAL DISTRESS

Contacts and locations

Locations

Bruyere Health
RECRUITING

Ottawa, Ontario, Canada
McGill University Health Centre
NOT_YET_RECRUITING

Montreal, Quebec, Canada
Providence Care Hospital
RECRUITING

Kingston, Ontario, Canada
South Lake Regional Health Centre
RECRUITING

Newmarket, Ontario, Canada
St. Joseph's Healthcare
NOT_YET_RECRUITING

London, Ontario, Canada
The Ottawa Hospital
NOT_YET_RECRUITING

Ottawa, Ontario, Canada
William Osler Health System
NOT_YET_RECRUITING

Brampton, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.